Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: Feasibility, safety and first insights on efficacy

Haematologica

Volumn 101, Issue 4, 2016, Pages e153-e156

  Rettinger, Eva ^a   Huenecke, Sabine ^a   Bonig, Halvard ^a,b   Merker, Michael ^a   Jarisch, Andrea ^a   Soerensen, Jan ^a   Willasch, Andre ^a   Bug, Gesine ^a   Schulz, Ansgar ^c   Klingebiel, Thomas ^a   Bader, Peter ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Cytokine induced killer cells; Efficacy; HSCT; IL 15 activated; Immunological control; Relapse

Indexed keywords

INTERLEUKIN 15;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CHILD; CLINICAL ARTICLE; CYTOKINE INDUCED KILLER CELL; FEASIBILITY STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LEUKEMIA; LEUKEMIA REMISSION; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; RECURRENCE FREE SURVIVAL; SCHOOL CHILD; YOUNG ADULT; AGED; ALLOTRANSPLANTATION; CLINICAL TRIAL; CYTOLOGY; DONOR; DRUG EFFECTS; GRAFT VS HOST DISEASE; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; INFANT; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MULTICENTER STUDY; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; RECURRENT DISEASE; REMISSION; TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CYTOKINE-INDUCED KILLER CELLS; FEMALE; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT; INTERLEUKIN-15; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; REMISSION INDUCTION; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84962447617     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.138016     Document Type: Letter

References (15)

1. Kanda J, Chao NJ, Rizzieri DA. Haploidentical transplantation for leukemia. Curr Oncol Rep. 2010; 12(5): 292-301.
2. Bader P, Kreyenberg H, von Stackelberg A, et al. Monitoring of Minimal Residual Disease After Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia Allows for the Identification of Impending Relapse: Results of the ALL-BFM-SCT 2003 Trial. J Clin Oncol. 2015; 33(11): 1275-1284.
3. Bader P, Kreyenberg H, Hoelle W, et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol. 2004; 22(9): 1696-1705.
4. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16): 1507-1517.
5. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991; 174(1): 139-149.
6. Pievani A, Borleri G, Pende D, et al. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood. 2011; 118(12): 3301-3310.
7. Lutz C, Massenkeil G, Nagy M, et al. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008; 41(9): 805-812.
8. Haines HL, Bleesing JJ, Davies SM, et al. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases. Biol Blood Marrow Transplant. 2015; 21(2): 288-292.
9. Zeidan AM, Forde PM, Symons H, et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2014; 20(3): 314-318.
10. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997; 15(2): 433-444.
11. Balduzzi A, Di Maio L, Silvestri D, et al. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? Br J Haematol. 2014; 164(3): 396-408.
12. Lankester AC, Bierings MB, van Wering ER, et al. Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia. 2010; 24(8): 1462-1469.
13. Linn YC, Niam M, Chu S, et al. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant. 2012; 47(7): 957-966.
14. Introna M, Borleri G, Conti E, et al. Repeated infusions of donorderived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica. 2007; 92(7): 952-959.
15. Laport GG, Sheehan K, Baker J, et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; 17(11): 1679-1687.